Resection of hepatitis B virus-related hepatocellular carcinoma:Evolving strategies and emerging therapies to improve outcome

摘要

The incidence of hepatocellular carcinoma(HCC) is increasing worldwide,largely due to hepatitis B virus(HBV),hepatitis C virus and liver cirrhosis.Chronic HBV infection is estimated to cause 55%-60% of the cases of HCC worldwide and over 70% in Asian countries.Liver resection is currently the mainstay of treatment due to the low surgical mortality,a wider treatment indication,and simplicity of post-treatment follow-up.There is an ever-increasing demand on surgeons to perform curative liver resection in HCC,with the hope of avoiding tumor recurrences.Hepatitis B-related-HCC has distinct clinicopathological features,which should be considered when treating the disease.The author presents a review of the recently evolving strategies and emerging therapies to improve HCC postresectional outcomes and focus on perioperative measures to improve patient outcome,with particular reference to the current status of adjuvant therapies in HCC patients after liver resection.